|Bid||5.32 x 1100|
|Ask||5.45 x 1000|
|Day's Range||5.40 - 5.51|
|52 Week Range||4.63 - 6.70|
|Beta (3Y Monthly)||0.93|
|PE Ratio (TTM)||8.34|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||9.00|
TASE: KMDA.TA), a plasma-derived protein therapeutics company, reports that it is currently in discussions with Takeda to extend the period prior to transitioning the manufacture of GLASSIA, Kamada’s proprietary product for the treatment of Alpha-1 Antitrypsin Deficiency, to Takeda. Kamada will provide additional information regarding the discussions, if appropriate, at a later date. As background, Kamada has supplied GLASSIA to Takeda, or its predecessors, since 2010. The GLASSIA supply agreement with Takeda currently extends through the end of 2020, followed by an expected transition of GLASSIA manufacturing to Takeda. While the transition of GLASSIA manufacturing to Takeda after 2020 will result in a significant reduction of Kamada’s revenues, based on the current terms of the supply agreement, Kamada would be entitled to future royalty payments until 2040.
Kamada (KMDA) delivered earnings and revenue surprises of 6.67% and 4.12%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Total Revenues for Second Quarter of 2019 were $35.3 Million, a 4% Increase Year-Over-YearTotal Revenues for First Six Months of 2019 were $62.1 Million, a 21% Increase.
REHOVOT, Israel, July 31, 2019 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results.
Kamada (KMDA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks.com featured highlights include: Kamada, Anhui Conch Cement, Air China and Air Transport Services
Cash is an indispensable factor for any company. It gives strength and vitality to a company and is the key to its existence, development and success.
Zacks.com featured highlights include: Kamada, SunCoke Energy, Great Lakes Dredge & Dock, Herc and SYNNEX
Cannabics Pharmaceuticals Inc (OTC: CNBX), a company focused on personalizing cannabinoid medicine, especially in relation to cancer and its side effects, this week announced the appointment of two new members of their board of directors: Dr. Estery Giloz-Ran and Eran Ballan. Giloz-Ran is a certified public accountant and holds a PhD in tax, accounting and finance from Ben-Gurion University in Israel.
Kamada (KMDA) delivered earnings and revenue surprises of 160.00% and 17.17%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
The Rehovot, Israel-based company said it had net income of 12 cents per share. Earnings, adjusted for stock option expense, came to 13 cents per share. The biopharmaceutical posted revenue of $26.8 million ...
Total Revenues for Q1 2019 were $26.8 Million, up 54% over Q1 2018Q1 2019 Proprietary Products Revenues up 67% Year-over-Year Gross Profit for Q1 2019 Grew 59%.
Kamada Ltd. (NASDAQ: KMDA ) releases its next round of earnings this Tuesday, May 14. Here's Benzinga's essential guide to Kamada's first-quarter earnings report. Earnings and Revenue Analysts covering ...
REHOVOT, Israel, May 07, 2019 -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company, today announced that it will release financial results.
Kamada (KMDA) wins the FDA acceptance for the path forward regarding its inhaled Alpha-1-Antitrypsin product, currently under development for treating Alpha-1 Antitrypsin Deficiency.
REHOVOT, Israel, April 16, 2019 -- Kamada Ltd. (Nasdaq & TASE: KMDA), a plasma-derived protein therapeutics company, today announced receipt of a letter from the U.S. Food.